PRA Health Sciences, Inc. (PRAH) Holdings Raised by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 3.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 915,111 shares of the medical research company’s stock after acquiring an additional 29,771 shares during the quarter. Russell Investments Group Ltd. owned about 1.44% of PRA Health Sciences worth $69,704,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. increased its stake in PRA Health Sciences by 28.2% during the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock worth $274,759,000 after acquiring an additional 805,573 shares during the last quarter. Capital Research Global Investors increased its stake in PRA Health Sciences by 318.3% during the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock worth $163,172,000 after acquiring an additional 1,655,336 shares during the last quarter. Ameriprise Financial Inc. increased its stake in PRA Health Sciences by 23.0% during the second quarter. Ameriprise Financial Inc. now owns 788,807 shares of the medical research company’s stock worth $59,166,000 after acquiring an additional 147,428 shares during the last quarter. State Street Corp increased its stake in PRA Health Sciences by 52.8% during the second quarter. State Street Corp now owns 782,800 shares of the medical research company’s stock worth $58,729,000 after acquiring an additional 270,530 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in PRA Health Sciences by 27.1% during the second quarter. Wells Fargo & Company MN now owns 774,620 shares of the medical research company’s stock worth $58,105,000 after acquiring an additional 165,105 shares during the last quarter. 97.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/18/pra-health-sciences-inc-prah-holdings-raised-by-russell-investments-group-ltd.html.

PRA Health Sciences, Inc. (NASDAQ:PRAH) traded up $0.80 on Friday, hitting $80.70. The stock had a trading volume of 383,938 shares, compared to its average volume of 505,183. PRA Health Sciences, Inc. has a 1-year low of $51.16 and a 1-year high of $84.38. The stock has a market capitalization of $5,110.00 and a price-to-earnings ratio of 28.89. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. PRA Health Sciences’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. research analysts expect that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current year.

PRAH has been the subject of several recent analyst reports. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Wednesday, August 30th. SunTrust Banks, Inc. restated a “buy” rating and set a $101.00 price target on shares of PRA Health Sciences in a research report on Friday, October 27th. Jefferies Group LLC restated a “buy” rating and set a $95.00 price target on shares of PRA Health Sciences in a research report on Thursday, October 26th. Finally, Credit Suisse Group restated an “outperform” rating and set a $90.00 price target (up from $84.00) on shares of PRA Health Sciences in a research report on Monday, October 16th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. PRA Health Sciences has an average rating of “Buy” and a consensus target price of $88.09.

In related news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply